# Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma

> **NCT06467097** · PHASE3 · RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 88 (estimated)

## Conditions studied

- Kidney Neoplasm

## Interventions

- **RADIATION:** SBRT(Stereotatic Body Radiation Therapy)

## Key facts

- **NCT ID:** NCT06467097
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2031-02-13
- **Final completion:** 2031-02-13
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06467097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06467097, "Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06467097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*